RESUMO
Objective To explore the correlation between air pollutants (PM2.5, NO2, and CO) and the mortality rate of HIV/AIDS patients in Wuhan. Methods The death data of HIV/AIDS patients from January 1, 2017, to December 31, 2019, and the daily average atmospheric pollutant concentration during the study period were collected. A time-stratified case-control study design was used to explore the correlation between atmospheric pollutant concentration and patient mortality. Results For every 10 µg/m3 increase in CO concentration within 0-4 days of cumulative lag, AIDS-related mortality in HIV/AIDS patients increased by 1.79% (95% CIs: 0.04, 3.56). There was no statistical correlation between PM3 and NO3 concentrations and mortality in patients with HI and AIDS. Conclusion CO is positively correlated with the risk of AIDS-related death in HIV/AIDS patients. This study can provide relevant epidemiological evidence for public health authorities to develop more effective prevention measures for HIV/AIDS patients.
RESUMO
Objective To investigate the prevalence and influencing factors of HIV/AIDS patients with hyperlipidemia before and after receiving antiviral therapy in Wuhan. Methods A retrospective cohort study was used to analyze the data of HIV/AIDS patients in Wuhan from 2004 to 2021. Elevated levels of either TG or TC were determined as hyperlipidemia. Logistic regression model was used to analyze the influencing factors of baseline hyperlipidemia, and Cox proportional risk model was used to analyze the influencing factors of new-onset hyperlipidemia after receiving antiviral therapy. Results A total of 7 562 HIV/AIDS patients were enrolled, 30.61% (2 315/7 562) with hyperlipidemia at baseline and 69.39% (5 247/7 562) without hyperlipidemia. The mean person-years of follow-up for those patients without hyperlipidemia at baseline were 3.48, of whom 33.14% (1 739/5 247) developed hyperlipidemia during follow-up, with an overall density of 9.53/100 person-years. Multivariate logistic regression analysis showed that age ≥30 years and BMI ≥24 kg/m2 were positively correlated with baseline hyperlipidemia, while CD4 cell count ≥ 200 μL was negatively correlated with baseline hyperlipidemia. Multivariate Cox model analysis showed that new-onset hyperlipidemia after receiving antiviral therapy was significantly positively correlated with BMI between 18.5-23.9 and ≥24 kg/m2, the initial antiviral treatment regimen containing LPV/r, efavirenz and other factors A baseline CD4 cell count of 200 to 349 cells /μL was negatively correlated with new-onset hyperlipidemia. Conclusion HIV/AIDS patients with high BMI and an initial antiviral regimen including Kaletra or efavirenz have a significantly higher risk of hyperlipidemia. Follow-up monitoring of blood lipid in these patients should be strengthened.
RESUMO
OBJECTIVETo evaluate the efficacy and safety of Chinese medicine (Q-14) plus standard care compared with standard care alone in adult with coronavirus disease 2019 (COVID-19). Study DESIGNSingle-center, open label, randomised controlled trial. SETTINGWuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020. PARTICIPANTS204 patients with laboratory confirmed COVID-19 were randomised in to treatment group and control group, which was 102 patients each group. INTERVENTIONSIn treatment group, Q-14 was administrated at 10g (granules), twice daily for 14 days and plus standard care. In control group, patients were given standard care alone for 14 days. MAIN OUTCOME MEASUREThe primary outcome was conversion time of SARS-CoV-2 viral assay. Adverse events were analyzed in the safety population. RESULTSAmong 204 patients, 195 were analyzed according to the intention to treat principle. There were 149 patients (71 vs. 78 in treatment group and control group respectively) turning to negative via SARS-CoV-2 viral assay. No statistically significance showed in conversion time between treatment group and control group (FAS: Median (IQR): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank: 67.92 vs. 81.44; P=0.051.). Time to recovery of fever was shorter in treatment group as compared in control group. The disappearance rate of symptom in cough, fatigue, chest discomfort was significantly higher in treatment group. In chest computed tomography (Chest CT) examinations, overall evaluation of chest CT examination after treatment compared with baseline showed more patients improved in treatment group .There were no significant differences in the other outcomes. CONCLUSIONAdministration of Q-14 on standard care for COVID-19 was useful for improvement of symptoms (such as fever, cough, fatigue and chest discomfort), while did not result in a significantly higher probability of negative conversion of SARS-CoV-2 viral assay. No serious adverse events were reported. TRIAL REGISTRATIONChiCTR2000030288
RESUMO
Objective:To study the effect of social support on depression-posttraumatic stress disorder(PTSD) comorbidity among people living with human immunodeficiency virus/acquired immunodeficiency syndrome(PLWHA).Methods:Using questionnaire to one-to-one investigate the newly-diagnosed PLWHA in Wuhan Jingyintan Hospital HIV/AIDS clinic from October 2016 to February 2019. The content of the questionnaire included general demographic characteristics, HIV-related high-risk behaviors before diagnosis, social support, depression and PTSD.Patients with depression and PTSD were collected as P+ D group.Patients without depression or PTSD were collected as N group. The statistical software was SPSS 21.0. Chi-square test, t test and rank sum test were used to compare the differences between the two groups, and multivariate Logistic regression analysis was used to identify the influencing factors of depression combined with PTSD. Results:Among 320 PLWHA, 72 subjects(22.50%) had depression with PTSD(P+ D group), 161 subjects(50.31%) had neither depression nor PTSD(N group). Between the two groups, the differences of constituent ratios of gender(χ 2=9.84), routes of infection(χ 2=11.16), whether ever used drug(χ 2=30.00)were statistically significant(all P<0.05). There were statistically significant differences in the scores of social support((30.64±10.90) vs (25.51±8.55)), objective social support((7.20±3.08) vs (5.76±2.24)), subjective social support((16.70±6.87) vs (14.04±5.61)) and utility of social support((6.74±2.59) vs (5.71±2.60)( t=3.56, 3.57, 2.88, 2.81, all P<0.05). The results of Logistic analysis revealed that gender as male( β=-1.48, OR= 0.23, 95% CI=0.09-0.61) was protective factor for depression co-occuring with PTSD, while lower level of social support ( β=1.40, OR=4.05, 95% CI=1.36-12.10) was a risk factor. Conclusion:The prevalence of depression co-occuring with PTSD in PLWHA is high. The influence of gender and social support should be paid more attention to PLWHA.
RESUMO
We aimed to explore the prevalence of and risk factors for depressive symptoms (DS) among people living with HIV/AIDS (PLWHA) receiving antiretroviral treatment (ART) in Wuhan, Hubei, China. A cross-sectional study evaluating adult PLWHA receiving ART in nine designated clinical hospitals was conducted from October to December 2015. The validated Beck Depression Inventory (BDI) was used to assess DS in eligible participants. Socio-demographical, epidemiological and clinical data were directly extracted from the case reporting database of the China HIV/AIDS Information Network. Multinomial regression analysis was used to explore the risk factors for DS. 394 participants were finally included in all analyses. 40.3% were found to have DS with 13.7% having mild DS and 26.6% having moderate to severe DS. The results of multinomial regression analysis suggested that being married or living with a partner, recent experience of ART-related side effects, and/or history of HCV infection were positively associated with mild DS, while increasing age was positively associated with moderate to severe DS.
